ReviewEFORT open reviews2023
Local recurrence management of extremity soft tissue sarcoma.
Review in EFORT open reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Application of quantitative imaging parameters combined with tertiary lymphoid structures in recurrence risk assessment of soft tissue sarcoma: a retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Review
- Prognostic impact of tumour-vessel proximity in soft tissue sarcoma: Fujiwara classification provides enhanced risk stratification.World journal of surgical oncology · 2026Article
- Organizing Care Matters: Fragmented Pathways Double Early Local Recurrence Risk in Sarcoma.Cancers · 2026Article
- Leiomyosarcomas of the Great Saphenous Vein: Diagnostic and Therapeutic Strategies to Prevent Unplanned Excisions and Improve Oncologic, Functional, and Psychological Outcomes.Diseases (Basel, Switzerland) · 2025Article
- Osseous invasion in extremity soft-tissue sarcomas: prevalence, diagnosis, and surgical management- A narrative review.Journal of bone oncology · 2025Review
- Preoperative Chemoradiation (Modified Eilber Protocol) Versus Preoperative/Postoperative Radiotherapy for Soft Tissue Sarcomas: A Population-Based Analysis.Current oncology (Toronto, Ont.) · 2025Article
- Neoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma?Current oncology reports · 2025Review
- Forearm Compartment Release with Incidental Soft Tissue Sarcoma.Journal of hand surgery global online · 2025Article
- Beyond the blood-brain barrier: feasibility and technical validation of dual-compartment circulating tumor cells detection in high-grade glioma patients.Neurosurgical review · 2025Article
- The Impact of Surgical Margin Distance on Local Recurrence and Survival in Patients with Soft Tissue Sarcoma.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Integrated Care in Specialized Networks: Leveraging Early Referrals to Reduce Local Recurrence in Soft Tissue Sarcoma.Cancers · 2024Article
- Enchondroma in the Fibular Diaphysis: A Case Report.Cureus · 2024Article
- Review on Lymph Node Metastases, Sentinel Lymph Node Biopsy, and Lymphadenectomy in Sarcoma.Current oncology (Toronto, Ont.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology. There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years. The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity. Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease's recurrence. The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.